T2 Biosystems (0A57) Share Price & Analysis

1 Followers

0A57 Stock Chart & Stats

$0.00-$0.15(-99.60%)

At close: Oct 02 3:09 PM GMT+1

Day’s Range: $0.15 - $0.15
52-Week Range: $0.15 - $0.15
Previous Close: $0.15
Volume: N/A
Average Volume (3M): 0
Market Cap: $252.41K
Enterprise Value: $52.11M
Total Cash (Recent Filing): $2.08M
Total Debt (Recent Filing): $18.94M
Price to Earnings (P/E): 0.0
Beta: 0.57
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The 34% revenue growth indicates strong demand for T2 Biosystems' products, suggesting effective market penetration and potential for sustained growth.

Strategic Partnerships

The partnership with Cardinal Health expands market access to over 6,000 U.S. hospitals, enhancing distribution capabilities and long-term sales potential.

Product Pipeline Developments

Advancements in the product pipeline, including FDA designations, position T2 Biosystems for future growth and market leadership in diagnostics.

Bears Say

Financial Instability

Negative equity and high leverage highlight financial instability, posing risks to operational sustainability and limiting strategic flexibility.

Cash Flow Challenges

Negative cash flow and reliance on external financing threaten long-term viability, potentially impacting the company's ability to fund operations and growth.

NASDAQ Compliance Issues

Non-compliance with NASDAQ listing requirements could lead to delisting, affecting investor confidence and access to capital markets.

T2 Biosystems News

One new option listing and option delistings on January 20th

New option listings for January 20th include Telefonica S.A. (TELFY). Option delistings effective January 20th include MSCI USA Gross Total Return USD Index (.MXUSA), MSCI World Net Total Return USD

9M agoCVM TEF

T2 Biosystems Delays Yearly Report Filing

T2 Biosystems ( ($TTOO) ) has released a notification of late filing. T2 Biosystems, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period

1y agoTTOO 3T2

T2 Biosystems Reduces Workforce Amid Nasdaq Delisting Notice

T2 Biosystems ( ($TTOO) ) has provided an announcement. On February 13, 2025, T2 Biosystems’ Board of Directors approved a significant reduction-in-force affecting nearly all employees, resulting in expected one-time

1y ago8K TTOO

Paychex to acquire Paycor HCM, Getty and Shutterstock to merge: Morning Buzz

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Paychex (PAYX) agreed to acquire Paycor HCM (PYCR) for

1y agoAUR GMM

T2 Biosystems reports preliminary Q4 revenue $2.3M

“We made considerable progress across the business during 2024, increasing our global installed base of T2Dx Instruments, and generating record sales for our sepsis test panels, including record U.S. sales

1y agoTTOO 3T2

T2 Biosystems Enhances Governance and Leadership Stability

T2 Biosystems ( ($TTOO) ) has provided an update. T2 Biosystems, Inc. held its annual meeting of stockholders, where key corporate governance matters were addressed, including the approval of an

1y ago8K TTOO

T2 Biosystems announces sale of four T2Dx Intruments to European distributor

T2 Biosystems (TTOO) announced the sale of four T2Dx Instruments to its European distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument

1y agoTTOO 3T2

T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped

T2 Biosystems (TTOO) announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company’s direct-from-whole-blood technology. A

1y agoTTOO 3T2

T2 Biosystems extends multi-year supplier agreement with Vizient

T2 Biosystems (TTOO) announced that its multi-year capital equipment supplier agreement with Vizient has been extended through March 31, 2026. The products covered under the contract with Vizient include the

1y agoTTOO 3T2

T2 Biosystems Advances Sepsis Detection Technology Licensing

T2 Biosystems ( ($TTOO) ) has issued an update. T2 Biosystems is set to expand its market leadership by licensing its cutting-edge technology for detecting sepsis-causing pathogens directly from whole

1y ago8K TTOO

T2 Biosystems announces plans to license technology to expand its leadership

T2 Biosystems (TTOO) announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Biosystems’ proprietary technology is a key component of its

1y agoTTOO 3T2

T2 Biosystems Reports Increased Losses and Cash Crunch

T2 Biosystems ( ($TTOO) ) has released its Q3 earnings. Here is a breakdown of the information T2 Biosystems presented to its investors. T2 Biosystems, Inc. is an innovative in

1y agoTTOO 3T2

TTOO Earnings this Week: How Will it Perform?

T2 Biosystems (TTOO) is scheduled to report 3rd quarter earnings on 11/14/2024, after the market closes. Regarding Q3 estimates, Wall Street analysts expect T2 Biosystems to post earnings of -$0.64

2y agoTTOO 3T2

T2 Biosystems, Prxcision announce co-marketing collaboration

T2 Biosystems and Prxcision have announced a co-marketing collaboration intended to deliver a revolutionary solution for patients suspected of bloodstream infections and sepsis, and combat the escalating crisis of antibiotic

2y agoTTOO 3T2

0A57 FAQ

What was T2 Biosystems’s price range in the past 12 months?

T2 Biosystems lowest share price was $0.15 and its highest was $0.15 in the past 12 months.

What is T2 Biosystems’s market cap?

T2 Biosystems’s market cap is $252.41K.

When is T2 Biosystems’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is T2 Biosystems overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does T2 Biosystems pay dividends?

T2 Biosystems does not currently pay dividends.

What is T2 Biosystems’s EPS estimate?

T2 Biosystems’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does T2 Biosystems have?

T2 Biosystems has 28,045,418 shares outstanding.

Which hedge fund is a major shareholder of T2 Biosystems?

Hedge funds hold T2 Biosystems shares: the largest hedge-fund position in T2 Biosystems is 1,628,358,246 shares.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

T2 Biosystems

T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus. In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloodstream infections caused by both bacterial and Candida species, along with antibiotic resistance markers; T2Cauris, which offers direct detection of the emerging superbug Candida auris in patient skin, blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel specifically engineered for the T2Dx Instrument to identify the bacteria responsible for Lyme disease. T2 Biosystems has also established strategic partnerships, such as its collaboration with Canon U.S. Life Sciences, Inc., to jointly develop a diagnostic test panel for Lyme disease. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

T2 Biosystems (0A57) Earnings & Revenues

Historic Earnings Reports

0A57 Earnings Call

Q3 2024

0:00 / 0:00

Earnings Call SentimentNeutral

T2 Biosystems demonstrated significant revenue growth and strategic partnerships, notably with Cardinal Health, which could drive future success. However, financial challenges such as a substantial net loss and NASDAQ compliance issues are concerning. The sentiment is balanced by the potential of new product launches and operational improvements.

View all GB:0A57 earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	7	3	4
Technical Analysis	1	1	0
Moving Averages	6	2	4

Technical Analysis >

Similar Stocks

Stocks similar to GB:0A57
Company	Price & Change	Follow
DHRDanaher
ILMNIllumina
QGENQiagen
DGXQuest Diagnostics
TMOThermo Fisher

Compare GB:0A57 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

0A57 Stock Chart & Stats

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Strategic Partnerships

Product Pipeline Developments

Bears Say

Financial Instability

Cash Flow Challenges

NASDAQ Compliance Issues

T2 Biosystems News

One new option listing and option delistings on January 20th

T2 Biosystems Delays Yearly Report Filing

T2 Biosystems Reduces Workforce Amid Nasdaq Delisting Notice

Paychex to acquire Paycor HCM, Getty and Shutterstock to merge: Morning Buzz

T2 Biosystems reports preliminary Q4 revenue $2.3M

T2 Biosystems Enhances Governance and Leadership Stability

T2 Biosystems announces sale of four T2Dx Intruments to European distributor

T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped

T2 Biosystems extends multi-year supplier agreement with Vizient

T2 Biosystems Advances Sepsis Detection Technology Licensing

T2 Biosystems announces plans to license technology to expand its leadership

T2 Biosystems Reports Increased Losses and Cash Crunch

TTOO Earnings this Week: How Will it Perform?

T2 Biosystems, Prxcision announce co-marketing collaboration

0A57 FAQ

Company Description

T2 Biosystems

T2 Biosystems (0A57) Earnings & Revenues

0A57 Earnings Call

Earnings Call Sentiment|Neutral

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentNeutral